Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. increased its stake in Bristol-Myers Squibb (NYSE:BMY) by 1.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,804 shares of the biopharmaceutical company’s stock after acquiring an additional 829 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Bristol-Myers Squibb were worth $4,910,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in BMY. Douglass Winthrop Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 6.0% in the 4th quarter. Douglass Winthrop Advisors LLC now owns 39,397 shares of the biopharmaceutical company’s stock worth $2,228,000 after buying an additional 2,217 shares in the last quarter. Holderness Investments Co. grew its holdings in Bristol-Myers Squibb by 5.2% during the fourth quarter. Holderness Investments Co. now owns 42,770 shares of the biopharmaceutical company’s stock worth $2,419,000 after acquiring an additional 2,128 shares during the period. Northwest & Ethical Investments L.P. lifted its holdings in Bristol-Myers Squibb by 354.6% in the 4th quarter. Northwest & Ethical Investments L.P. now owns 73,499 shares of the biopharmaceutical company’s stock valued at $4,157,000 after acquiring an additional 57,331 shares during the last quarter. iA Global Asset Management Inc. boosted its position in shares of Bristol-Myers Squibb by 28.6% during the 4th quarter. iA Global Asset Management Inc. now owns 98,732 shares of the biopharmaceutical company’s stock valued at $5,584,000 after purchasing an additional 21,957 shares in the last quarter. Finally, Magnetar Financial LLC grew its stake in shares of Bristol-Myers Squibb by 540.4% in the 4th quarter. Magnetar Financial LLC now owns 216,407 shares of the biopharmaceutical company’s stock worth $12,240,000 after purchasing an additional 182,616 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 1,823 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were bought at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.09% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BMY shares. Citigroup raised their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Friday, February 7th. Cantor Fitzgerald upped their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Bank of America reissued a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Finally, Truist Financial raised their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock opened at $61.06 on Friday. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The firm has a fifty day simple moving average of $58.17 and a 200-day simple moving average of $55.89. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The stock has a market capitalization of $123.92 billion, a price-to-earnings ratio of -13.82, a PEG ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.06%. Bristol-Myers Squibb’s payout ratio is -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.